Product Summary
CJC-1295 (CAS 863288-34-0) is a synthetically engineered growth hormone-releasing hormone (GHRH) analog, specifically designed to overcome the limitations of native GHRH, which has an extremely short plasma half-life due to rapid enzymatic degradation [3]. Its molecular structure incorporates strategic modifications that significantly enhance its stability and prolong its biological activity in preclinical research settings [1]. A key feature of its design is the addition of a Drug Affinity Complex (DAC), which allows the peptide to bind reversibly to albumin in the bloodstream, dramatically extending its half-life and enabling sustained release [2].
This prolonged activity profile makes CJC-1295 an invaluable research tool for investigating the effects of sustained GHRH stimulation on the hypothalamic-pituitary axis. By promoting a more natural, pulsatile release of endogenous growth hormone (GH) over an extended period, it facilitates the study of GH and insulin-like growth factor 1 (IGF-1) physiology without the need for frequent dosing [2]. Its research applications are primarily focused on understanding metabolic regulation, body composition modulation, and the mechanisms of anabolic growth processes.
Furthermore, its enhanced stability against enzymatic degradation, achieved through amino acid substitutions (such as the replacement of alanine with D-alanine at position 2), allows researchers to maintain elevated GH levels for several days, providing a consistent model for studying the downstream effects of GH secretion on various tissues and metabolic pathways [3]. As such, CJC-1295 continues to be a critical compound in endocrinology and metabolism research for exploring potential therapeutic strategies related to growth hormone deficiency and metabolic disorders.
Physicochemical Profile
| Property | Specification |
|---|---|
| Product Designation | CJC-1295 |
| Physical Characteristics | White lyophilized powder |
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Mass | 3367.0 g/mol |
| CAS Registry Number | 863288-34-0 |
| Purity Assessment | >98.0% (HPLC methodology) |
| Stability Period | 36 months (proper storage conditions) |
| Solvation Properties | Soluble in bacteriostatic water |
| Storage Requirements | -20°C, protected from light and humidity |
Key Attributes
- Exceptional Purity: Rigorous quality assessment utilizing reverse-phase high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) confirms purity levels exceeding 98.0%, ensuring reliable research outcomes and experimental reproducibility [1].
- Optimized Stability: The lyophilized formulation demonstrates enhanced stability profiles, maintaining structural integrity and biological activity when stored at recommended temperatures (-20°C), thereby preserving research functionality throughout extended study durations [2].
- Synthetic Production: Manufactured through advanced solid-phase peptide synthesis technology, this process guarantees exceptional batch-to-batch consistency while effectively eliminating risks associated with biological contaminants including endotoxins and microbial agents [3].
- Research Application: Specifically engineered for controlled laboratory investigations, this compound is suitable for various research models including in vitro cellular assays and physiological mechanism studies, providing consistent performance across experimental conditions [1].
Reviews
Research Implications
Note: The following research observations are derived from published preclinical studies. This material is exclusively for research purposes and not for human consumption.
Scientific investigation utilizing CJC-1295 has contributed significantly to multiple research domains through its unique pharmacological properties [2,3,4]:
- Endocrine Modulation Studies: Enables detailed examination of growth hormone pulsatile secretion patterns and their complex regulatory mechanisms, providing insights into hypothalamic-pituitary axis functionality [3].
- Metabolic Pathway Research: Facilitates exploration of nutrient partitioning mechanisms and metabolic process regulation, particularly regarding lipid metabolism and protein synthesis pathways in experimental models [4].
- Receptor Dynamics Analysis: Supports comprehensive investigation of growth hormone-releasing hormone (GHRH) receptor interactions and subsequent intracellular signaling cascade activation, contributing to understanding of receptor-ligand kinetics [2].
- Compound Stability Research: Provides valuable insights into peptide modification strategies and structural optimization approaches for enhanced research applicability and prolonged investigation periods [3].
Research Applications
CJC-1295 serves multiple investigative purposes across various scientific disciplines, demonstrating particular utility in the following areas [1,3,5]:
- Endocrinology Investigations: Employed in sophisticated studies examining growth hormone pulsatility characteristics and complex endocrine feedback mechanisms, contributing to understanding of hormonal regulation systems [3].
- Metabolic Research: Utilized in exploring intricate relationships between growth hormone activity and metabolic regulation processes, particularly in studies investigating energy homeostasis and substrate utilization [5].
- Pharmaceutical Development: Serves as valuable reference material for developing sustained-release peptide formulations and optimizing delivery systems for research compounds [1].
- Physiological Studies: Applied in advanced research investigating hormone secretion patterns and their physiological effects on various body systems and metabolic functions [3].
- Biochemical Research: Employed in detailed studies examining peptide stability parameters and receptor binding kinetics, contributing to understanding of molecular interaction mechanisms [5].
CJC-1295 vs. Tesamorelin: A Comparison
Similarities
- Common Target and Mechanism: Both are synthetic analogs of Growth Hormone-Releasing Hormone (GHRH). They primarily work by binding to GHRH receptors on the pituitary gland, stimulating the synthesis and release of endogenous growth hormone (GH).
- Endogenous GH Secretion: Unlike administering synthetic growth hormone directly, both peptides promote the body's own pulsatile secretion of GH, which is considered a more physiological and natural pattern.
- Primary Research Focus: Their primary research applications are closely aligned, focusing on metabolic studies, body composition regulation (particularly reducing visceral adipose tissue), and understanding GH-related pathways.
- Improved Stability: Both peptides are engineered to be more stable and have a longer duration of action than native GHRH, which is rapidly degraded by enzymes in the body.
Differences
| Feature | CJC-1295 | Tesamorelin |
|---|---|---|
| Primary Structure | A modified version of GHRH (1-29) fragment. | Consists of the full 44 amino acid sequence of GHRH with a specific trans-3-hexenoic acid modification. |
| Key Modification | Drug Affinity Complex (DAC): Allows it to bind reversibly to albumin in the bloodstream. | Amino Acid Substitution: Features a specific alteration to enhance stability and receptor binding. |
| Half-Life & Activity | Sustained-Release: The DAC modification grants it a very long half-life (several days), leading to a prolonged and sustained release of GH. | Short-Acting: Has a significantly shorter half-life (minutes to a few hours). Requires more frequent administration to maintain effect. |
| Release Profile | Promotes a sustained elevation of GH levels, resulting in a correspondingly prolonged increase in IGF-1. | Designed to mimic the natural pulsatile secretion of GH more closely, with sharper peaks following each dose. |
| Research Emphasis | Often studied for its ability to provide continuous GH stimulation, useful for investigating long-term anabolic and metabolic effects. | Heavily researched in specific clinical contexts, most notably for treating HIV-associated lipodystrophy and its selective reduction of visceral fat. |
| Regulatory Status | Primarily a research chemical, not approved for therapeutic use in major markets. | FDA-Approved: Approved under the brand name Egrifta® for the treatment of excess abdominal fat in HIV patients with lipodystrophy. |
Frequently Inquired Aspects
Q: What is the primary research advantage of CJC-1295 compared to other GHRH analogs?
A: CJC-1295 features a unique molecular modification that enables drug affinity complex (DAC) technology, providing extended half-life and sustained activity in research settings. This allows for less frequent dosing in prolonged studies investigating growth hormone pulsatility.
Q: How is the purity of your CJC-1295 verified?
A: Each batch undergoes comprehensive analytical testing using high-performance liquid chromatography (HPLC) and mass spectrometry, with certificates of analysis available upon request confirming >98.0% purity.
Q: What is the recommended reconstitution procedure for research purposes?
A: For research applications, reconstitute with bacteriostatic water to desired concentration. Typical research concentrations range from 1-5 mg/mL. Always use sterile techniques and store reconstituted peptide at 2-8°C for short-term use.
Q: Do you provide supporting documentation for research compliance?
A: Yes, we provide complete documentation including certificates of analysis, material safety data sheets, and research use statements to ensure compliance with institutional regulations.
Q: Are there any specific storage considerations for long-term stability?
A: For optimal preservation, store unopened vials at -20°C in desiccated conditions. Avoid repeated freeze-thaw cycles as this may affect peptide integrity.
Q: What research models has CJC-1295 been utilized in?
A: This compound has been employed in various research models including in vitro cellular assays, animal metabolic studies, and endocrine system investigations, primarily focusing on growth hormone mechanisms.
Q: What payment options are available for research institutions?
A: We accept various payment methods including wire transfers, credit cards, and institutional purchase orders.
Certification
How To Contact Us?
Our company is a professional supplier of semi-finished materials, including plant extracts, fruit and vegetable powder, cosmetics, tablet candy, and other products. Our products are directly supplied from the manufacturer, so the price is very favorable, and the quality is guaranteed so that you can buy with confidence.
Now our company is hot-selling CJC-1295, if you are interested in this product and want to know about it, you can consult our account manager through the international website or email. Our email address is ella.zhang@huilinbio-tech.com.
Reference Citations
[1] National Center for Biotechnology Information. PubChem Compound Summary for CID 16165308
[2] Teichman, S. L., et al. (2006). Endocrine Reviews, 27(4), 431-438
[3] Jetté, L., et al. (2005). Journal of Endocrinology, 185(3), 479-488
[4] Research on metabolic effects of growth hormone modulation
[5] Studies on peptide therapeutics and their research applications
Usage Disclaimer
This product is intended exclusively for research purposes in controlled laboratory environments. It is not intended for diagnostic, therapeutic, or human use. Purchasers must ensure compliance with all applicable regulations governing research materials. Xi'an Huilin Biological Technology Co., Ltd. assumes no liability for misuse or unauthorized handling of this material.
Hot Tags: CJC-1295 Peptide Powder, China, suppliers, manufacturers, factory, wholesale, buy, price, bulk, pure, natural, high quality, in stock, for sale
